DYNLL1 INHIBITS DNA END RESECTION IN BRCA1-DEFICIENT CELLS AND REGULATES PARP INHIBITOR SENSITIVITY

被引：0

作者：

He, Yizhou Joseph ^{[1
]}

Meghani, Khyati ^{[1
]}

Caron, Marie-Christine ^{[2
,3
]}

Yang, Chunyu ^{[1
]}

Ronato, Daryl A. ^{[2
,3
]}

Bian, Jie ^{[1
]}

Sharma, Anchal ^{[4
]}

Miller, Jessica ^{[1
]}

Joshi, Niraj ^{[1
]}

Detappe, Alexandre ^{[5
]}

Doench, John G. ^{[6
]}

Legube, Gaelle ^{[7
]}

Root, David E. ^{[6
]}

D'Andrea, Alan D. ^{[1
,8
]}

Drane, Pascal ^{[1
]}

De, Subhojyoti ^{[4
]}

Konstantinopoulos, Panagiotis ^{[5
]}

Masson, Jean-Yves ^{[2
,3
]}

Chowdhury, Dipanjan ^{[1
,6
,9
]}

机构：

[1] Harvard Med Sch, Dana Farber Canc Inst, Dept Radiat Oncol, Div Radiat & Genome Stabil, Boston, MA 02215 USA

[2] CHU Quebec Res Ctr, Genome Stabil Lab, Oncol Axis, HDQ Pavil,9 McMahon, Quebec City, PQ G1R 2J6, Canada

[3] Laval Univ, Canc Res Ctr, Dept Mol Biol Med Biochem & Pathol, Quebec City, PQ G1V 0A6, Canada

[4] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[5] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

[6] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA

[7] Univ Toulouse, CNRS, CBI, LBCMCP,UT3, 118 Route Narbonne, F-31062 Toulouse, France

[8] Harvard Med Sch, Dana Farber Canc Inst, Ctr DNA Damage & Repair, Boston, MA 02215 USA

[9] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA

来源：

CLINICAL CANCER RESEARCH | 2019年 / 25卷 / 22期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

GMM-027

引用

页码：90 / 90

页数：1

共 50 条

[21] Brca1-deficient murine mammary epithelial cells have increased sensitivity to CDDP and MMS
Sgagias, MK
Wagner, KU
Hamik, B
Stoeger, S
Spieker, R
Huber, LJ
Chodosh, LA
Cowan, KH
CELL CYCLE, 2004, 3 (11) : 1451 - 1456
[22] Brca1-deficient ovarian cancer cells are sensitized to the DNA-strand-breaking nucleoside analog sapacitabine that synergizes with PARP inhibition
Liu, Xiaojun
Jiang, Yingjun
Nowak, Billie
Tikhomirova, Dariya
Plunkett, William
CANCER RESEARCH, 2015, 75
[23] Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice
Zhang, Di
Singh, Bijay
Moerland, Jessica
Mitchell, Owen
Lockwood, Lizbeth
Carapellucci, Sarah
Sridhar, Srinivas
Liby, Karen T.
SCIENTIFIC REPORTS, 2021, 11 (01)
[24] Olaparib and veliparib as effective PARP inhibitors for cancer prevention in a BRCA1-deficient mouse model
To, Ciric
Williams, Charlotte R.
Royce, Darlene B.
Collins, Ryan M.
Sporn, Michael B.
Liby, Karen T.
CANCER RESEARCH, 2014, 74 (19)
[25] 53BP1 loss mediated PARP inhibitor resistance in BRCA1-deficient pancreatic cancer is overcome with immune checkpoint blockade
Patterson-Fortin, Jeffrey
Sun, Yajie
Han, Sen
Li, Zhe
Nowicka, Zuzanna
Hirohashi, Yuna
Kilgas, Susan
Yi, Jae Kyo
Spektor, Alexander
Fendler, Wojciech
Konstantinopoulos, Panagiotis
D'Andrea, Alan D.
Chowdhury, Dipanjan
CANCER RESEARCH, 2024, 84 (01)
[26] PARP inhibition modulates the tumor immune microenvironment in Brca1-deficient ovarian tumor.
Ding, Liya
Wang, Qiwei
Kearns, Michael
Jiang, Tao
Konstantinopoulos, Panagiotis
Matulonis, Ursula
Zhao, Jean
CLINICAL CANCER RESEARCH, 2020, 26 (13) : 23 - 23
[27] Targeting GPX4-mediated ferroptosis protection sensitizes BRCA1-deficient cancer cells to PARP inhibitors
Xie, Xuexia
Chen, Congcong
Wang, Cong
Guo, Yongjian
Sun, Binghe
Tian, Jiaxin
Yan, Jin
Li, Dake
Chen, Guo
REDOX BIOLOGY, 2024, 76
[28] Cell cycle checkpoints in BRCA1-deficient embryonic stem cells
Snouwaert, JN
Pace, AJ
Gowen, LC
Xiao, A
Nichols, MA
Xiong, Y
Koller, BH
FASEB JOURNAL, 1999, 13 (07): : A1538 - A1538
[29] Akt1 inhibits homologous recombination in Brca1-deficient cells by blocking the Chk1-Rad51 pathway
Jia, Y.
Song, W.
Zhang, F.
Yan, J.
Yang, Q.
ONCOGENE, 2013, 32 (15) : 1943 - 1949
[30] Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia
Nieborowska-Skorska, Margaret
Maifrede, Silvia
Ye, Min
Toma, Monika
Hewlett, Elizabeth
Gordon, John
Bac Viet Le
Sliwinski, Tomasz
Zhao, Huaqing
Piwocka, Katarzyna
Valent, Peter
Tulin, Alexei V.
Childers, Wayne
Skorski, Tomasz
LEUKEMIA & LYMPHOMA, 2019, 60 (04) : 1098 - 1101

← 1 2 3 4 5 →